These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 18062718)

  • 21. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
    Jacobsen P; Rossing K; Parving HH
    Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CS-886, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats.
    Koga K; Yamagishi S; Takeuchi M; Inagaki Y; Amano S; Okamoto T; Saga T; Makita Z; Yoshizuka M
    Mol Med; 2002 Oct; 8(10):591-9. PubMed ID: 12477969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sulodexide therapy for the treatment of diabetic nephropathy, a meta-analysis and literature review.
    Li R; Xing J; Mu X; Wang H; Zhang L; Zhao Y; Zhang Y
    Drug Des Devel Ther; 2015; 9():6275-83. PubMed ID: 26664049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of anemia in patients with type II diabetes and mild to moderate chronic kidney disease and the impact of anti-RAS medications.
    Dousdampanis P; Trigka K; Fourtounas C
    Saudi J Kidney Dis Transpl; 2014 May; 25(3):552-7. PubMed ID: 24821151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FPIN's clinical inquiries. Angiotensin blockade in patients with diabetic nephropathy.
    Jimenez J; Safranek S; Viera AJ
    Am Fam Physician; 2007 Aug; 76(3):423-4. PubMed ID: 17708144
    [No Abstract]   [Full Text] [Related]  

  • 26. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy.
    Packham DK; Wolfe R; Reutens AT; Berl T; Heerspink HL; Rohde R; Ivory S; Lewis J; Raz I; Wiegmann TB; Chan JC; de Zeeuw D; Lewis EJ; Atkins RC;
    J Am Soc Nephrol; 2012 Jan; 23(1):123-30. PubMed ID: 22034636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal protection and antihypertensive drugs: current status.
    Salvetti A; Mattei P; Sudano I
    Drugs; 1999 May; 57(5):665-93. PubMed ID: 10353294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Agents in development for the treatment of diabetic nephropathy.
    Goh SY; Jasik M; Cooper ME
    Expert Opin Emerg Drugs; 2008 Sep; 13(3):447-63. PubMed ID: 18764722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retarding the progression of diabetic nephropathy in type 2 diabetes mellitus: focus on hypertension and proteinuria.
    Lee GS
    Ann Acad Med Singap; 2005 Jan; 34(1):24-30. PubMed ID: 15726216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preventing end-stage renal disease in diabetic patients - dual blockade of the renin-angiotensin system (Part II).
    Jacobsen PK
    J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):55-68. PubMed ID: 16470484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A trial of the use of the low-molecular heparin sulodexide in the therapy of diabetic nephropathy].
    Zalevskaia AG; Astamirova KhS; Karpova IA; Popova SG
    Ter Arkh; 1998; 70(3):71-4. PubMed ID: 9575594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of sulodexide on albuminuria, NAG excretion and glomerular filtration response to dopamine in diabetic patients.
    Sulikowska B; Olejniczak H; Muszyńska M; Odrowaz-Sypniewska G; Gaddi A; Savini C; Cicero AF; Laghi L; Manitius J
    Am J Nephrol; 2006; 26(6):621-8. PubMed ID: 17191008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients.
    Cooper ME
    J Hypertens Suppl; 1996 Dec; 14(6):S11-4. PubMed ID: 9023709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glycosaminoglycans: use in treatment of diabetic nephropathy.
    Gambaro G; VAN DER Woude FJ
    J Am Soc Nephrol; 2000 Feb; 11(2):359-368. PubMed ID: 10665944
    [No Abstract]   [Full Text] [Related]  

  • 35. Renin angiotensin system blockade and nephropathy: why is it being called into question, and should it be?
    Hollenberg NK; Epstein M
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1046-8. PubMed ID: 17699325
    [No Abstract]   [Full Text] [Related]  

  • 36. Renal effects of dual renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy.
    Dalla Vestra M; Simioni N; Masiero A
    Int Urol Nephrol; 2009; 41(1):119-26. PubMed ID: 18958580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ACE inhibitors and diabetic nephropathy: clinical and experimental findings.
    Hasslacher C; Kempe HP; Bostedt-Kiesel A
    Clin Investig; 1993; 71(5 Suppl):S20-4. PubMed ID: 8518536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control.
    Hunsicker LG
    J Manag Care Pharm; 2004 Sep; 10(5 Suppl A):S12-7. PubMed ID: 15369420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
    Zanella MT; Ribeiro AB
    Clin Ther; 2002 Jul; 24(7):1019-34. PubMed ID: 12182249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D
    Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.